Companies ›Health Care ›MGX.AX

MGX.AX — ASX Biotechnology & Life-Science Tools

MGX Resources Ltd

A$0,34

Open in Charts → Attach watcher ⌖

— —

AUD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

MGX Resources Ltd is a mining company focused on the exploration and development of mineral resources, primarily in the iron and steel industry.

Business. MGX Resources Ltd (MGX.AX) is a biotechnology and life-science tools company listed on the Australian Securities Exchange. The firm operates within the Health Care sector, focusing on the development and sale of biotechnology products. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the biotechnology and life-science tools market.

Classification99 %

SectorHealth Care

Industry groupBiotechnology & Life-Science Tools

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning MGX.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,7 %+1,5 %

Communication Services+2,2 %−5,5 %+1,5 %

Energy+0,9 %+5,2 %+0,1 %

Health Care · THIS SECTOR+0,7 %−0,8 %−0,1 %

Information Technology+0,2 %+8,1 %−0,5 %

Consumer Discretionary+0,2 %+8,7 %−0,6 %

Financials−0,3 %−2,8 %−1,0 %

Consumer Staples−0,6 %+2,2 %−1,3 %

Real Estate−0,7 %+10,9 %−1,5 %

Industrials−1,1 %−0,3 %−1,9 %

Utilities−1,9 %+28,2 %−2,6 %

Developing storylines

No tracked sagas currently linked to MGX.AX. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-07-26 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

MGX Resources Ltd (MGX.AX) is a biotechnology and life-science tools company listed on the Australian Securities Exchange. The firm operates within the Health Care sector, focusing on the development and sale of biotechnology products. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the biotechnology and life-science tools market.

Classification99 %

SectorHealth Care

Industry groupBiotechnology & Life-Science Tools

AI synthesis

GENERATED

MGX Resources Ltd has an equal number of basic and diluted shares outstanding, with 1,180,428,735 shares in both categories, indicating no immediate dilution pressure from stock options or convertible securities. However, the liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.

The company's profitability and returns metrics are not available in the valuation snapshot, making it difficult to compare its performance against industry_config preferred metrics or cohort medians. Without these metrics, it is challenging to assess whether MGX Resources Ltd is outperforming or underperforming its peers in the Iron & Steel industry.

MGX Resources Ltd's revenue concentration and geographic exposure are not disclosed in the available data, which limits the ability to evaluate the company's risk from over-reliance on specific markets or regions. This lack of transparency could pose a challenge for investors seeking to understand the company's exposure to regional economic fluctuations.

The company's growth trajectory is also unclear, as there are no numeric deltas or revenue history provided in the outlook. Without this information, it is difficult to determine whether MGX Resources Ltd is on a path of expansion or contraction in the current and next fiscal years.

The risk assessment indicates a low level of dilution risk, but the liquidity risk remains unassessed. The absence of balance-sheet inputs and the lack of going-concern language in the source documents suggest that the company's financial health and ability to meet short-term obligations are not well understood.

Recent events, including filings and transcripts, are not available in the provided data, which limits the ability to assess any recent developments that may impact the company's operations or financial position. This lack of information could affect the company's valuation and investor sentiment.

Key takeaways

MGX Resources Ltd has no immediate dilution pressure as basic and diluted shares are equal.
The company's liquidity risk could not be assessed due to missing balance-sheet data.
Profitability and returns metrics are not available, making it difficult to compare with industry peers.
Revenue concentration and geographic exposure are not disclosed, limiting understanding of regional risk.
Growth trajectory and recent events are not quantified, affecting the ability to assess future performance.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Annual

ANNUALFiled 2024-08-21

FY 2024 · Full-year highlights

Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 684.5M, +51,2% YoY; Operating income +72,2% YoY.

RevenueUNKNOWN ERROR IN UNIVERSE PROCESSING 684.5M+51,2 % YoY

Operating incomeUNKNOWN ERROR IN UNIVERSE PROCESSING 52.5M+72,2 % YoY

Net incomeUNKNOWN ERROR IN UNIVERSE PROCESSING 6.4M+24,2 % YoY

Free cash flowUNKNOWN ERROR IN UNIVERSE PROCESSING 67.5M+25,1 % YoY

EPS—

Operating cash flowUNKNOWN ERROR IN UNIVERSE PROCESSING 328.2M+152,3 % YoY

Financials

Income statement

RevenueUNKNOWN ERROR IN UNIVERSE PROCESSING 684.5M

Gross profitUNKNOWN ERROR IN UNIVERSE PROCESSING 193.1M

Operating incomeUNKNOWN ERROR IN UNIVERSE PROCESSING 52.5M

Net incomeUNKNOWN ERROR IN UNIVERSE PROCESSING 6.4M

Margins

Gross margin28.2%

Operating margin7.7%

Net margin0.9%

FCF margin9.9%

Balance sheet

Total assetsUNKNOWN ERROR IN UNIVERSE PROCESSING 664.3M

Total liabilitiesUNKNOWN ERROR IN UNIVERSE PROCESSING 118.1M

Total equityUNKNOWN ERROR IN UNIVERSE PROCESSING 546.2M

Cash & equivalents—

Long-term debtUNKNOWN ERROR IN UNIVERSE PROCESSING 11.9M

Cash flow

Operating cash flowUNKNOWN ERROR IN UNIVERSE PROCESSING 328.2M

CapEx-UNKNOWN ERROR IN UNIVERSE PROCESSING 60.9M

Free cash flowUNKNOWN ERROR IN UNIVERSE PROCESSING 67.5M

SBC—

P&L flow · revenue → net income

Highlights

▍Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 684.5M, +51,2% YoY
▍Operating income +72,2% YoY
▍Net income +24,2% YoY
▍Free cash flow +25,1% YoY
▍Net margin 0.9%

Valuation FY

Market price

A$0,34

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs MGX · multiples and returns

IQV—

Iqvia Holdings Inc

$210,49

35,7B USD

P/E

23,4x

— vs self

Div yield

—

— vs self

ROE

20,9 %

+76,3 vs self

CRL—

Charles River Laboratories

$229,29

11,3B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-4,6 %

+50,8 vs self

MEDP—

Medpace Holdings Inc

$608,00

17,6B USD

P/E

34,4x

— vs self

Div yield

—

— vs self

ROE

75,4 %

+130,8 vs self

ALKS—

Alkermes PLC

$52,66

8,7B USD

P/E

39,8x

— vs self

Div yield

—

— vs self

ROE

8,4 %

+63,8 vs self

PIII—

P3 Health Partners Inc

$9,62

69,6M USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

95,3 %

+150,7 vs self

ORGO—

Organogenesis Holdings Inc

$2,39

307,5M USD

P/E

9,0x

— vs self

Div yield

—

— vs self

ROE

8,5 %

+63,9 vs self

NAGE—

Niagen Bioscience Inc

$3,21

255,7M USD

P/E

17,4x

— vs self

Div yield

—

— vs self

ROE

22,7 %

+78,1 vs self

SPRY—

Ars Pharmaceuticals Inc

$5,94

589,8M USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-149,9 %

-94,5 vs self

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic

Source documents

MGX Resources Ltd Market data — financials · 2026-05-28

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

MGX.AXCanonical

ASX · AUD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

Net margin (FY 2025-12-31): -348.5%Derived (calculated)
Return on equity (FY 2025-12-31): -55.4%Derived (calculated)
Return on assets (FY 2025-12-31): -39.7%Derived (calculated)
Current ratio (FY 2025-12-31): 7.22xDerived (calculated)
Debt-to-equity (FY 2025-12-31): 0.39xDerived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): -81.6%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 52.3%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 0.0%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 0.0%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): -12.6%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 18.5%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): -8.0%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): -13.5%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): -51.8%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -32.5%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): -31.9%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -30.3%Derived (calculated)
EPS (diluted) (annual): USD-PER-SHARES -2SEC XBRL filing
R&D expense (annual): USD 94.43MSEC XBRL filing
Operating income (annual): USD -96.01MSEC XBRL filing
Shares outstanding (annual): 37.62MSEC XBRL filing
Current liabilities (annual): USD 22.93MSEC XBRL filing
Capex (annual): USD 574KSEC XBRL filing
Current assets (annual): USD 165.54MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-07-28EVENTUpcomingQ2 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)

2026-06-21 02:57 UTCHOLDERInstitutional holding changed

2026-06-21 02:57 UTCHOLDER3 institutional position changes flagged

2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated

2026-06-10FILING8-K filing →

2026-06-09 00:00 UTCINSIDER7 insider transactions — 2026-06 4 derivative

2026-06-09INSIDERDere Willard H acquired 21.0k sh Stock Option (Right to Buy) — Director

2026-06-09INSIDERReid Laurence acquired 17.4k sh Stock Option (Right to Buy) — Director

2026-06-09INSIDEREckhardt Juergen acquired 21.0k sh Stock Option (Right to Buy) — Director

2026-06-09INSIDERBJERKHOLT ERIC acquired 21.0k sh Stock Option (Right to Buy) — Director

2026-06-05INSIDERWapnick Pamela sold 2.9k sh — Chief Financial Officer ~$4k

2026-06-05INSIDERIrish Jian sold 3.7k sh — Director, See Remarks ~$5k

2026-06-05INSIDERWein Matthew sold 558 sh — See Remarks ~$1k

2026-05-11FILING10-Q filing →

2026-05-11FILING8-K filing →

2026-04-27FILINGDEF 14A filing →

2026-04-01 00:00 UTCINSIDER6 insider transactions — 2026-04 3 derivative

2026-04-01INSIDERIrish Jian transacted 46.0k sh — Director, See Remarks

2026-04-01INSIDERWein Matthew transacted 11.0k sh — See Remarks

2026-04-01INSIDERWapnick Pamela transacted 24.0k sh — Chief Financial Officer

2026-04-01INSIDERIrish Jian acquired 276.0k sh Stock Option (Right to Buy) — Director, See Remarks

2026-04-01INSIDERWein Matthew acquired 68.0k sh Stock Option (Right to Buy) — See Remarks

2026-04-01INSIDERWapnick Pamela acquired 144.0k sh Stock Option (Right to Buy) — Chief Financial Officer

2026-03-05 00:00 UTCINSIDER3 insider transactions — 2026-03

2026-03-05FILING10-K filing →

Showing the 40 most recent of 71 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-07-26 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread